Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01642706|
Recruitment Status : Recruiting
First Posted : July 17, 2012
Last Update Posted : October 14, 2019
|Condition or disease|
|Rheumatoid Arthritis Osteoarthritis Systemic Lupus Erythematosus Sjogren's Syndrome Scleroderma Spondylitis Gout Spinal Disease Chondrocalcinosis|
|Study Type :||Observational|
|Estimated Enrollment :||240 participants|
|Official Title:||Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments|
|Actual Study Start Date :||July 2, 2012|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||October 2020|
Patients affected by Rheumatoid arthritis.
Subjects affected by either :
- Assessment of Bregs levels [ Time Frame: 30 months ]The levels of Bregs will be assessed in patients with RA and compared to subjects with mechanical pathologies.
- Change of Bregs levels after therapy [ Time Frame: 30 months ]The levels of Bregs will be assessed in patients who will start a therapy within the framework of their usual follow-up.
Biospecimen Retention: Samples Without DNA
Comparison of Bregs levels
Lymphocytes will be analyzed from :
- circulating blood
- articular serum
- synovial membrane
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642706
|Contact: Jacques Morel, MD, PhDemail@example.com|
|Contact: Claire Daien, MDfirstname.lastname@example.org|
|Principal Investigator:||Jacques Morel, MD, PhD||University Hospital, Montpellier|